How many mutant p53 molecules are needed to inactivate a tetramer?

被引:139
作者
Chan, WM [1 ]
Siu, WY [1 ]
Lau, A [1 ]
Poon, RYC [1 ]
机构
[1] Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1128/MCB.24.8.3536-3551.2004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor p53 is transcription factor composed of four identical subunits. The majority of the mutations in p53 are missense mutations that impair DNA binding. On the other hand, the p53-related p63 and p73 genes are rarely mutated, but many cell types express natural variants lacking the N-terminal transactivation domain (NDelta). Compelling evidence indicates that both the DNA binding-defective and NDelta mutants can impair the function of wild-type p53 in a dominant-negative manner. Interestingly, it is uncertain how many mutant subunit(s) a p53 tetramer can tolerate. In this study, we first made theoretical predictions based on the number of mutant p53 monomers needed to inactivate a tetramer and then tested how well the experimental data fit the predicted values. Surprisingly, these experiments reveal that DNA binding-defective p53 mutants (R249S and R273H) are very ineffective in impairing the transcriptional activity of p53: at least three mutants are required to inactivate a tetramer. In marked contrast, p53NDelta is a very potent inhibitor of p53: one NDelta subunit per tetramer is sufficient to abolish the transcriptional activity. DNA binding is not necessary for the NDelta proteins to inactivate p53. Similarly, NDelta variants of p63 and p73 are also powerful inhibitors of members of the p53 family. These results have important implications for our thinking about the mechanism of tumorigenesis involving missense p53 mutants or the N-terminally truncated isoforms.
引用
收藏
页码:3536 / 3551
页数:16
相关论文
共 54 条
[1]   p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines [J].
Aurelio, ON ;
Kong, XT ;
Gupta, S ;
Stanbridge, EJ .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (03) :770-778
[2]  
Ausubel F.M., 1991, CURRENT PROTOCOLS MO
[3]  
BODNER SM, 1992, ONCOGENE, V7, P743
[4]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[5]   DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase [J].
Chow, JPH ;
Siu, WY ;
Fung, TK ;
Chan, WM ;
Lau, A ;
Arooz, T ;
Ng, CP ;
Yamashita, K ;
Poon, RYC .
MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (10) :3989-4002
[6]   p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 [J].
Davison, TS ;
Vagner, C ;
Kaghad, M ;
Ayed, A ;
Caput, D ;
Arrowsmith, CH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18709-18714
[7]   Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function [J].
de Vries, A ;
Flores, ER ;
Miranda, B ;
Hsieh, HM ;
van Oostrom, CTM ;
Sage, J ;
Jacks, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2948-2953
[8]   Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53 [J].
Denissenko, MF ;
Pao, A ;
Tang, MS ;
Pfeifer, GP .
SCIENCE, 1996, 274 (5286) :430-432
[9]  
ELIYAHU D, 1988, ONCOGENE, V3, P313
[10]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093